Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 9 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Sun Yat-sen University currently manages 9 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 9 distinct examiners. The prosecution spans 9 distinct art units, reflecting the technical distribution of the company's Biotechnology & Pharmaceuticals filings. This distribution across 9 distinct art units indicates that the company's active matters are subject to the specific standards of those assigned art units at the patent office.
The busiest examiner for this portfolio is GHORISHI, SEYED BEHROOZ, who is responsible for 1 pending office action. This count of 1 pending office action for the busiest examiner is part of the total 9 pending office actions. With 9 distinct examiners involved, practitioners managing this portfolio must coordinate across individual examiner preferences. The fact that GHORISHI, SEYED BEHROOZ handles this workload highlights the distribution of the current prosecution pipeline. This requires a strategy that accounts for the requirements of the 9 distinct examiners across the 9 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (56%) |
| §103 only | 1 (11%) |
| Multi-statute (no §101) | 3 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GHORISHI, SEYED BEHROOZ | 1 | 69.0% | +43.7% |
| BERKE-SCHLESSEL, DAVID W | 1 | 66.8% | +31.5% |
| VALENROD, YEVGENY | 1 | 72.5% | +25.1% |
| CREWS, JARET JAMES | 1 | 43.9% | +71.3% |
| CUTLIFF, YATE KAI RENE | 1 | 79.8% | +24.3% |
| COCCHI, MICHAEL EDWARD | 1 | 40.9% | +47.7% |
| NEGIN, RUSSELL SCOTT | 1 | 55.9% | +34.2% |
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
| HARVEY, MINSUN OH | 1 | 69.8% | +2.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18318728 | DFB LASER MANUFACTURING METHOD BASED ON DIELECTRIC LATERALLY COUPLED GRATING WITH DETERMINISTIC GRATING COUPLING COEFFICIENT | HARVEY, MINSUN OH | 30d |
| 18999089 | METHOD, APPARATUS, DEVICE, AND MEDIUM FOR SIMULATINGPOLYURETHANE PERMEATION GROUTING DIFFUSION | GHORISHI, SEYED BEHROOZ | — |
| 18959230 | BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS, MICROBIAL AGENT AND USE THEREOF | BERKE-SCHLESSEL, DAVID W | — |
| 18726951 | 1-AMINOBENZO[4,5]IMIDAZO[1,2-A]PYRAZINE-3-FORMAMIDE COMPOUND, AND PREPARATION THEREFOR AND USE THEREOF | VALENROD, YEVGENY | — |
| 17619922 | METHOD FOR PREPARING PT-BASED ALLOY / MOFS CATALYST WITH HIGH HYDROGENATION SELECTIVITY AND APPLICATION THEREOF | CUTLIFF, YATE KAI RENE | — |
| 18280945 | METHOD AND SYSTEM FOR ANALYZING PRECIPITATION NORMALIZATION BY GRADIENT-BASED PARAMETER OPTIMIZATION | COCCHI, MICHAEL EDWARD | — |
| 18232363 | METHOD AND DEVICE FOR CONSTRUCTING AUTISM SPECTRUM DISORDER (ASD) RISK PREDICTION MODEL | NEGIN, RUSSELL SCOTT | — |
| 18325792 | BIOMARKER FOR DIAGNOSIS, TREATMENT, AND PROGNOSIS FOR HEPATOCELLULAR CARCINOMA BONE METASTASIS AND APPLICATION THEREOF | PUTTLITZ, KARL J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18999089 | METHOD, APPARATUS, DEVICE, AND MEDIUM FOR SIMULATINGPOLYURETHANE PERMEATION GROUTING DIFFUSION | GHORISHI, SEYED BEHROOZ | — |
| 18959230 | BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS, MICROBIAL AGENT AND USE THEREOF | BERKE-SCHLESSEL, DAVID W | — |
| 18726951 | 1-AMINOBENZO[4,5]IMIDAZO[1,2-A]PYRAZINE-3-FORMAMIDE COMPOUND, AND PREPARATION THEREFOR AND USE THEREOF | VALENROD, YEVGENY | — |
| 18717426 | USE OF SODIUM FORMATE IN PREPARATION OF AN ANTI-INFECTIVE DRUG | CREWS, JARET JAMES | — |
| 17619922 | METHOD FOR PREPARING PT-BASED ALLOY / MOFS CATALYST WITH HIGH HYDROGENATION SELECTIVITY AND APPLICATION THEREOF | CUTLIFF, YATE KAI RENE | — |
| 18280945 | METHOD AND SYSTEM FOR ANALYZING PRECIPITATION NORMALIZATION BY GRADIENT-BASED PARAMETER OPTIMIZATION | COCCHI, MICHAEL EDWARD | — |
| 18232363 | METHOD AND DEVICE FOR CONSTRUCTING AUTISM SPECTRUM DISORDER (ASD) RISK PREDICTION MODEL | NEGIN, RUSSELL SCOTT | — |
| 18325792 | BIOMARKER FOR DIAGNOSIS, TREATMENT, AND PROGNOSIS FOR HEPATOCELLULAR CARCINOMA BONE METASTASIS AND APPLICATION THEREOF | PUTTLITZ, KARL J | — |
| Art Unit | Apps |
|---|---|
| 1748 | 1 |
| 1651 | 1 |
| 1628 | 1 |
| 1691 | 1 |
| 1692 | 1 |
| 2188 | 1 |
| 1686 | 1 |
| 1646 | 1 |
| 2828 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18999089 | METHOD, APPARATUS, DEVICE, AND MEDIUM FOR SIMULATINGPOLYURETHANE PERMEATION GROUTING DIFFUSION | GHORISHI, SEYED BEHROOZ | 1748 | §101§103§112 | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18959230 | BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS, MICROBIAL AGENT AND USE THEREOF | BERKE-SCHLESSEL, DAVID W | 1651 | §101§112 | Non-Final OA | — | Pending | Nov 25, 2024 |
| 18726951 | 1-AMINOBENZO[4,5]IMIDAZO[1,2-A]PYRAZINE-3-FORMAMIDE COMPOUND, AND PREPARATION THEREFOR AND USE THEREOF | VALENROD, YEVGENY | 1628 | §102§112 | Non-Final OA | — | Pending | Jul 05, 2024 |
| 18717426 | USE OF SODIUM FORMATE IN PREPARATION OF AN ANTI-INFECTIVE DRUG | CREWS, JARET JAMES | 1691 | §103 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 17619922 | METHOD FOR PREPARING PT-BASED ALLOY / MOFS CATALYST WITH HIGH HYDROGENATION SELECTIVITY AND APPLICATION THEREOF | CUTLIFF, YATE KAI RENE | 1692 | §102§103§112 | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18280945 | METHOD AND SYSTEM FOR ANALYZING PRECIPITATION NORMALIZATION BY GRADIENT-BASED PARAMETER OPTIMIZATION | COCCHI, MICHAEL EDWARD | 2188 | §101§112 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18232363 | METHOD AND DEVICE FOR CONSTRUCTING AUTISM SPECTRUM DISORDER (ASD) RISK PREDICTION MODEL | NEGIN, RUSSELL SCOTT | 1686 | §101§103 | Non-Final OA | — | Pending | Aug 10, 2023 |
| 18325792 | BIOMARKER FOR DIAGNOSIS, TREATMENT, AND PROGNOSIS FOR HEPATOCELLULAR CARCINOMA BONE METASTASIS AND APPLICATION THEREOF | PUTTLITZ, KARL J | 1646 | §101§103§112 | Non-Final OA | — | Pending | May 30, 2023 |
| 18318728 | DFB LASER MANUFACTURING METHOD BASED ON DIELECTRIC LATERALLY COUPLED GRATING WITH DETERMINISTIC GRATING COUPLING COEFFICIENT | HARVEY, MINSUN OH | 2828 | §102§103 | Non-Final OA | 30d | Pending | May 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSun Yat-sen University has 9 pending office actions as of October 2026, spread across 9 art units and 9 examiners.
Seyed Behrooz Ghorishi has the most, with 1 of Sun Yat-sen University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
